Oncology and Hematology Drugs
Application:
|
Drug Name |
Application |
|
KidiPeg |
Reducing the possibility of infections by stimulating the production of granulocytes in patients with non-myeloid malignancies who receive myelosuppression drugs and are highly likely to contract febrile neutropenia. |
|
PegaGen |
Reducing the chances of infection in patients who receive myelosuppressant chemotherapy and are exposed to higher risks of febrile neutropenia. |
|
CinnaPoietin |
* Treating anemia in patients with chronic failure of the kidney * Preventing anemia in premature infants * Anemia treatment in adults who undergo chemotherapy to treat their cancer * Increasing autologous blood before donation |
Product Introduction:
* KidiPeg: It is the trademark of filgrastim. The product is offered for intravenous injection and is similar to neupogen.
* PegaGen: PegaGen is the trademark under which pegfilgrastim is offered. It is used for intravenous injection and is similar to neupogen.
* CinnaPoietin: It is the trademark of erythropoietin, which is used for subcutaneous or intravenous injection. The brand name of the drug is Neoncoremone.
Technical Specifications:
* KidPeg: Each syringe contains 3mg pegfilgrastim in 0.3ml packages.
* PegaGen: Each simple or physioject syringe contains 6mg pegfilgrastin in 0.6ml packages.
* CinnaPoietin: Each syringe contains colorlessand transparent solution free from any particles.
| Main Export Destinations | Austria, Azerbaijan, England, Georgia, Germany, India, Iraq, Kazakhstan, Lebanon, Moldova, Nigeria, Pakistan, Russia, Sri Lanka, Switzerland, Syria, Tajikistan, Turkey, United Arab Emirates, Uzbekistan |
|---|---|
| Company | |
| Type | These products are final B2B & B2C consumer products. |
Related Products
Application:
|
Medicine Name |
Application |
|
Filgrastim recombinant protein (Tinagrast) |
* Treatment of chemotherapy-induced neutropenia in patients with non-myeloid malignant cancers who receive anticancer drugs that deplete bone marrow. * Adjuvant therapy for patients having bone marrow transplant surgery to hasten myeloid recovery * Treatment of resistant neutropenia in HIV infections at advanced stages * Treating severe chronic neutropenia |
|
Filgrastim Recombinant Protein (Tinapeg) |
Treatment of neutropenia (lack of white blood cells) caused by consumption of anticancer drugs |
|
Filgrastim recombinant protein (Tinakid) |
Strengthening the body’s defence and returning it to normal |
Application:
* Preventing the accumulation or creation of viruses that cause all types of cervical, anal, vaginal or vulva cancers.
* Preventing genital warts
Application:
* Cinnovex, Recigen, and Cinnomer: Prescribing for the recurrent types of MS to reduce the frequency and intensity of the attacks and lower the progress speed of disability
* Cinnotec: Treating the recurrent form of Multiple Sclerosis (MS)
Application:
Treating Treatment of the 2HER-positive breast cancer in early stages, metastatic 2HER-positive instances of breast cancer, and metastatic 2HER-positive instances of the stomach cancer.
Application:
|
Drug Name |
Applications |
|
Cinnal-F |
* Follicle-stimulating hormone (FSH) * The stimulation of ovulation * Treating infertility |
|
CinnaFact |
* Analog to the Gonadotropin-releasing hormone (GnRH) * The artificial analog of GnRH * Anti-neoplasm * Stimulating ovulation |
|
Cinnatropin |
* Supplying the growth hormone in children and adults with a growth hormone deficiency * Supplying the growth hormone in short children with Turner syndrome * Supplying the growth hormone in the body to achieve the convenient growth of young patients with chronic failure of kidney * Supplying the growth hormone for small gestational age (SGA) children who do not conveniently grow until 2-4 years old. |
|
Melitide |
* Reducing blood glucose levels in children aged above 10 and adults with type II diabetes * Reducing the risk of cardiovascular events like strokes, myocardial infarctions, and death in patients with type II diabetes and cardiovascular diseases |
Application:
* Cinnora: Treating rheumatoid arthritis
* Cinnopar: Reducing the risk of the fracture of one’s bones, particularly hip bone of post-menopausal women with osteoporosis, reducing the risk of bone fractures in hypogonadal men and women or the ones in the early stages of osteoporosis, reducing the risk of bone fractures in patients whose osteoporosis arises from the repeated consumption of glucocorticoids
Application:
* Treatment of Juvenile rheumatoid arthritis
* Alleviating the pain in patients with Rheumatoid arthritis
Application:
This product is used for adult patients with heart attack, stroke, and pulmonary embolism. This drug should be taken ASAP after the stroke (preferably up to 4-5 hours after the onset of stroke symptoms) to achieve the desired result. ALTEPLASE has a relatively small effect on free, circulating plasminogen and can be called a fibrinspecific thrombolytic. In recent years, this drug has played a significant role in saving the lives of patients and reducing the damage caused by these perilous diseases. Specialists have found that in patients with stroke, for every minute that treatment with this product starts faster, 1.8 days will be added to the patient’s life without disability (DFLE).
Application:
Controlling and preventing the symptoms of hemophilia type A or classic hemophilia.
Application:
Treatment of Non-Hodgkin Lymphoma (NHL), chronic lymphoid leukemia (CLL), rheumatoid arthritis, Granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA)